The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.
CHUCKYSCARNAGE 